Match!
Georg Schett
University of Erlangen-Nuremberg
1,036Publications
88H-index
32.4kCitations
Publications 1036
Newest
Published on 2019in Arthritis Research & Therapy4.15
E. Kampylafka1
Estimated H-index: 1
(FAU: University of Erlangen-Nuremberg),
David Simon7
Estimated H-index: 7
(FAU: University of Erlangen-Nuremberg)
+ 7 AuthorsGeorg Schett88
Estimated H-index: 88
(FAU: University of Erlangen-Nuremberg)
A specific subset of psoriasis patients is characterized by subclinical inflammatory changes. These patients frequently present with arthralgia and have a higher risk to develop psoriatic arthritis (PsA). We hypothesized that IL-17A inhibition in this subset of patients can intercept the link between skin and joint disease and resolves pain and inflammatory changes. Psoriasis, but no PsA, patients were included in the open prospective exploratory Interception in very early PsA (IVEPSA) study. Pa...
Published on Jan 22, 2019in Arthritis Research & Therapy4.15
Ernest Choy50
Estimated H-index: 50
(Cardiff University),
Xenofon Baraliakos39
Estimated H-index: 39
(RUB: Ruhr University Bochum)
+ 8 AuthorsMichael Rissler1
Estimated H-index: 1
(Novartis)
Spondyloarthritis comprises a group of inflammatory diseases, characterised by inflammation within axial joints and/or peripheral arthritis, enthesitis and dactylitis. An increasing number of biologic treatments, including biosimilars, are available for the treatment of spondyloarthritis. Although there are a growing number of randomised controlled trials assessing treatments in spondyloarthritis, there is a paucity of data from head-to-head studies. Comparative data are required so that clinici...
Published on Dec 1, 2019in Arthritis Research & Therapy4.15
Arthur Kavanaugh72
Estimated H-index: 72
(UCSD: University of California, San Diego),
Dafna D. Gladman100
Estimated H-index: 100
(Toronto Western Hospital)
+ 6 AuthorsPhilip J. Mease81
Estimated H-index: 81
(UW: University of Washington)
The efficacy and safety of apremilast were assessed in patients with psoriatic arthritis (PsA) in three phase III clinical trials with similar designs (PALACE 1, 2, and 3). Following a 24-week, randomized (1:1:1 to apremilast 30 mg twice daily, 20 mg twice daily, or placebo), double-blind phase and a 28-week blinded active treatment phase, patients could receive apremilast in open-label extension studies for an additional 4 years. Eligible adult patients had active PsA for ≥ 6 months and three o...
Published on Dec 1, 2019in Arthritis Research & Therapy4.15
David Simon7
Estimated H-index: 7
(FAU: University of Erlangen-Nuremberg),
Arnd Kleyer14
Estimated H-index: 14
(FAU: University of Erlangen-Nuremberg)
+ 9 AuthorsJuergen Rech16
Estimated H-index: 16
(FAU: University of Erlangen-Nuremberg)
Objectives To address whether the use of methotrexate (MTX) and biological disease-modifying anti-rheumatic drugs (bDMARDs) impacts bone structure and biomechanical properties in patients with psoriatic arthritis (PsA).
Published on May 5, 2019in Rheumatology5.15
Frédéric Toussaint (FAU: University of Erlangen-Nuremberg), Matthias Hammon8
Estimated H-index: 8
(FAU: University of Erlangen-Nuremberg)
+ 5 AuthorsLucie Heinzerling22
Estimated H-index: 22
(FAU: University of Erlangen-Nuremberg)
Published on Sep 20, 2019in Annals of the Rheumatic Diseases14.30
Alexandru-Emil Matei2
Estimated H-index: 2
(FAU: University of Erlangen-Nuremberg),
Chih-Wei Chen6
Estimated H-index: 6
(FAU: University of Erlangen-Nuremberg)
+ 11 AuthorsJan Hansmann11
Estimated H-index: 11
(Fraunhofer Society)
Objectives Fibrosis is a complex pathophysiological process involving interplay between multiple cell types. Experimental modelling of fibrosis is essential for the understanding of its pathogenesis and for testing of putative antifibrotic drugs. However, most current models employ either phylogenetically distant species or rely on human cells cultured in an artificial environment. Here we evaluated the potential of vascularised in vitro human skin equivalents as a novel model of skin fibrosis a...
Published on Sep 12, 2019in Orthopade0.63
Johannes Knitza1
Estimated H-index: 1
,
Arnd Kleyer14
Estimated H-index: 14
+ 1 AuthorsBernhard Manger45
Estimated H-index: 45
Published on Sep 11, 2019in Frontiers in Immunology4.72
Jasmin Knopf3
Estimated H-index: 3
,
Moritz Leppkes8
Estimated H-index: 8
+ 2 AuthorsLuis E. Muñoz33
Estimated H-index: 33
In response to various infectious and sterile stimuli neutrophils release chromatin decorated with bactericidal proteins, referred to as NETs. Their scaffolds are formed from chromatin fibers which display an apparent diameter of 15–17 nm and mainly consist from DNA (2 nm) and DNA-associated histones (11 nm). The NET-forming strands are thus not naked DNA but higher ordered chromatin structures. The histones may be released from the NET, especially if their tail arginines have been citrullinated...
Published on Sep 9, 2019in Annals of the Rheumatic Diseases14.30
David Bursill1
Estimated H-index: 1
(University of Adelaide),
William J. Taylor43
Estimated H-index: 43
+ 76 AuthorsAnthony M. Reginato11
Estimated H-index: 11
(Brown University)
Objective There is a lack of standardisation in the terminology used to describe gout. The aim of this project was to develop a consensus statement describing the recommended nomenclature for disease states of gout. Methods A content analysis of gout-related articles from rheumatology and general internal medicine journals published over a 5-year period identified potential disease states and the labels commonly assigned to them. Based on these findings, experts in gout were invited to participa...
Published on Sep 2, 2019in Journal of Leukocyte Biology4.01
Malgorzata Justyna Podolska6
Estimated H-index: 6
(FAU: University of Erlangen-Nuremberg),
Aparna Mahajan3
Estimated H-index: 3
(FAU: University of Erlangen-Nuremberg)
+ 9 AuthorsMartin Herrmann63
Estimated H-index: 63
(FAU: University of Erlangen-Nuremberg)
12345678910